A rationally designed form of the TLR5 agonist, flagellin, supports superior immunogenicity of Influenza B globular head vaccines

Vaccine

Volumn 32, Issue 34, 2014, Pages 4317-4323

  Song, Langzhou ^a   Liu, Ge ^a   Umlauf, Scott ^a   Liu, Xiangyu ^a   Li, Hong ^a   Tian, Haijun ^a   Reiserova, Lucia ^a   Hou, Fuxiang ^a   Bell, Rodney ^a   Tussey, Lynda ^a  

^a VaxInnate Corporation   (United States)

Author keywords

Flagellin domain 3 insertion; HA globular head; Influenza B vaccine

Indexed keywords

FLAGELLIN; HEMAGGLUTINATION INHIBITING ANTIBODY; INFLUENZA VACCINE; INTERLEUKIN 6; TOLL LIKE RECEPTOR 5; TUMOR NECROSIS FACTOR; HYBRID PROTEIN; INFLUENZA VIRUS HEMAGGLUTININ;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY TITER; ARTICLE; CONFORMATIONAL TRANSITION; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; CYTOKINE PRODUCTION; DRUG DESIGN; DRUG EFFICACY; DRUG MANUFACTURE; FEMALE; GENE EXPRESSION SYSTEM; HEMAGGLUTINATION INHIBITION; HEMAGGLUTINATION INHIBITION TEST; IMMUNE RESPONSE; IMMUNOGENICITY; IN VIVO STUDY; INFLUENZA VACCINATION; INFLUENZA VIRUS A H1N1; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROKARYOTIC EXPRESSION SYSTEM; PROTEIN DOMAIN; PROTEIN REFOLDING; SEASONAL INFLUENZA; SIGNAL TRANSDUCTION; VIRUS STRAIN; AGONISTS; AMINO ACID SEQUENCE; ANIMAL; BAGG ALBINO MOUSE; IMMUNOLOGY; INFLUENZA VIRUS B; MOLECULAR GENETICS; ORTHOMYXOVIRIDAE INFECTIONS; PROTEIN TERTIARY STRUCTURE; SERODIAGNOSIS;

AMINO ACID SEQUENCE; ANIMALS; FEMALE; FLAGELLIN; HEMAGGLUTINATION INHIBITION TESTS; HEMAGGLUTININ GLYCOPROTEINS, INFLUENZA VIRUS; INFLUENZA B VIRUS; INFLUENZA VACCINES; MICE, INBRED BALB C; MOLECULAR SEQUENCE DATA; NEUTRALIZATION TESTS; ORTHOMYXOVIRIDAE INFECTIONS; PROTEIN STRUCTURE, TERTIARY; RECOMBINANT FUSION PROTEINS; TOLL-LIKE RECEPTOR 5;

EID: 84903819825     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2014.06.013     Document Type: Article

References (17)

1. Janeway C.A., Medzhitov R. Innate immune recognition. Annu Rev Immunol 2002, 20:197-216.
2. Kawai T., Akira S. The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors. Nat Immunol 2010, 11(May (5)):373-384.
3. Medzhitov R., Janeway C. Innate immunity. N Engl J Med 2000, 343(August (5)):338-344.
4. Kawai T., Akira S. The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors. Nat Immunol 2010, 11(May (5)):373-384.
5. Iwasaki A., Medzhitov R. Toll-like receptor control of the adaptive immune responses. Nat Immunol 2004, 5(October (10)):987-995.
6. Hayashi F., Smith K.D., Ozinsky A., Hawn T.R., Yi E.C., Goodlett D.R., et al. The innate immune response to bacterial flagellin is mediated by Toll-like receptor 5. Nature 2001, 410(April (6832)):1099-1103.
7. Mizel S.B., Snipes J.A. Gram-negative flagellin-induced self-tolerance is associated with a block in interleukin-1 receptor-associated kinase release from toll-like receptor 5. J Biol Chem 2002, 277(June (25)):22414-22420.
8. Moors M.A., Li L., Mizel S.B. Activation of interleukin-1 receptor-associated kinase by gram-negative flagellin. Infect Immun 2001, 69(July (7)):4424-4429.
9. Yonekura K., Maki-Yonekura S., Namba K. Complete atomic model of the bacterial flagellar filament by electron cryomicroscopy. Nature 2003, 424(August (6949)):643-650.
10. Smith K.D., Andersen-Nissen E., Hayashi F., Strobe K., Bergman M.A., Barrett S.L., et al. Toll-like receptor 5 recognizes a conserved site on flagellin required for protofilament formation and bacterial motility. Nat Immunol 2003, 4(December (12)):1247-1253.
11. Yoon S.I., Kurnasov O., Natarajan V., Hong M., Gudkov A.V., Osterman A.L., et al. Structural basis of TLR5-flagellin recognition and signaling. Science 2012, 335(February (6070)):859-864.
12. Taylor D.N., Treanor J.J., Sheldon E.A., Johnson C., Umlauf S., Song L., et al. Development of VAX128, a recombinant hemagglutinin (HA) influenza-flagellin fusion vaccine with improved safety and immune response. Vaccine 2012, 30(August (39)):5761-5769.
13. Song L., Nakaar V., Kavita U., Price A., Huleatt J., Tang J., et al. Efficacious recombinant influenza vaccines produced by high yield bacterial expression: a solution to global pandemic and seasonal needs. PLoS ONE 2008, 3(5):e2257.
14. Song L., Zhang Y., Yun N.E., Poussard A.L., Smith J.N., Smith J.K., et al. Superior efficacy of a recombinant flagellin:H5N1 HA globular head vaccine is determined by the placement of the globular head within flagellin. Vaccine 2009, 27(September (42)):5875-5884.
15. Liu G., Song L., Reiserova L., Trivedi U., Li H., Liu X., et al. Flagellin-HA vaccines protect ferrets and mice against H5N1 highly pathogenic avian influenza virus (HPAIV) infections. Vaccine 2012, 30(November (48)):6833-6838.
16. Kendal A.P., Cate T.R. Increased sensitivity and reduced specificity of hemagglutination inhibition tests with ether-treated influenza B/Singapore/222/79. J Clin Microbiol 1983, 18(October (4)):930-934.
17. Treanor J.J., Campbell J.D., Zangwill K.M., Rowe T., Wolff M. Safety and immunogenicity of an inactivated subvirion influenza A (H5N1) vaccine. N Engl J Med 2006, 354(March (13)):1343-1351.